Actelion publish series of orexin 1/ orexin 2 receptor antagonists

Actelion have published a series of N-glycine-sulfonamides as potent dual orexin 1/ orexin 2 receptor antagonists

Tracleer (bosentan) approved in EU for Pulmonary Arterial Hypertension

Actelion Ltd have announced today that its endothelin receptor antagonist Tracleer (bosentan) has been approved in the EU for the treatment of patients with mildly symptomatic pulmonary arterial hypertension (PAH)

GlaxoSmithKline license Actelions orexin receptor antagonist almorexant

Actelion and GlaxoSmithKline have entered into exclusive collaboration for development of orexin receptor antagonist almorexant. Almorexant is currently in phase III development as a treatment for primary insomnia.

Bosentan receives positive EU opinion for treatment of patients with mildly symptomatic WHO Functional Class II pulmonary arterial hypertension

Actelion have announced that Bosentan (Tracleer) has received a positive EU opinion for treatment of patients with mildly symptomatic WHO Functional Class II pulmonary arterial hypertension (PAH)

Bosentan prevents clinical deterioration in mildly symptomatic PAH patients

Data published in the Lancet show Actelion’s Endothelin antagonist Bosentan (Tracleer) to prevent clinical deteriorationd in mildly symptomatic pulmonary arterial hypertension (PAH) patients